Epogen for horses

 

Epogen 2ml

EPO - Epoetin alpha-a glycoprotein that specifically stimulates erythropoiesis, activates mitosis and maturation of red blood cells from erythrocyte progenitor cells.

The introduction of epoetin alpha leads to an increase in hemoglobin and hematocrit, improving blood supply to tissues and heart function.

Recombinant human erythropoietin is a purified glycoprotein. Stimulates erythropoiesis. It is synthesized in mammalian cells, in which the gene encoding human erythropoietin is embedded. In terms of biological and immunological properties, it is identical to human erythropoietin released from urine. The synthesis of endogenous erythropoietin is carried out in the kidneys and depends on the level of blood oxygenation.

 

Epogen Used for treatment:

• anemia in patients with chronic renal failure, including those on hemodialysis;
• prevention and treatment of anemia in patients with solid tumors whose anemia was the result of antitumor therapy;
• prevention and treatment of anemia in patients infected with the human immunodeficiency virus (HIV), caused by the use of zidovudine, at the level of endogenous erythropoietin less than 500 IU / ml;
• prevention and treatment of anemia in patients with myeloma, low-grade non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and patients with rheumatoid arthritis;
• treatment and prevention of anemia in premature babies born with a low body weight up to 1.5 kg;
• as part of a pre-exposure program before extensive surgery in patients with a hematocrit level of 33-39%, to facilitate the collection of autologous blood and reduce the risk associated with the use of allogeneic blood transfusions, if the expected need for transfused blood exceeds the amount that can be obtained by autologous collection without the use of epoetin Alfa;
• before performing an extensive operation with an expected blood loss of 900-1800 ml in adult patients who do not have anemia or with mild to moderate anemia (hemoglobin level 100-130 g/l) to reduce the need for allogeneic hemotransfusions and facilitate the recovery of erythropoiesis.

 

Dosage:

Eralfon (Epoetin alpha, EPO, Erythropoietin) - is administered subcutaneously or intravenously at the end of a dialysis session. When changing the method of administration, the drug is administered in the same dose, then the dose is adjusted if necessary (with a subcutaneous method of administration, a dose of 20-30 % less is required to achieve the same therapeutic effect than with intravenous administration)